Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;15(4):294-7.
doi: 10.4103/2230-8210.85581.

Pioglitazone: Indian perspective

Rishi Shukla  1 , Sanjay Kalra
Affiliations

Pioglitazone: Indian perspective

Rishi Shukla et al. Indian J Endocrinol Metab. 2011 Oct.

Abstract

Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance. Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin, and C-reactive protein levels. These make pioglitazone treatment effective beyond glucose control. Pioglitazone generally has been viewed as a safer option for patients who warrant treatment with a thiazolidinedione-class drug. There has been some recent data on cancer incidence in patients on pioglitazone, which is currently being reviewed by drug regulatory authorities in the United States and in Europe. Given the benefits of pioglitazone, alone and in combination, it would be appropriate to continue judicious use of the drug in patients who may benefit from its use.

Keywords: Bladder cancer; India; cardiovascular benefits; pioglitazone.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil.

References

    1. Peters AL. Using Thiazolidinediones: Rosiglitazone and pioglitazone in clinical practice. Am J Manag care. 2001;7(3 Suppl):S87–95. quiz S96-7. - PubMed
    1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–18. - PubMed
    1. Gale EA. Lessons from the glitazones: A story of drug development. Lancet. 2001;357:1870–5. - PubMed
    1. Taylor C, Hobbs FD. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. Br J Gen Pract. 2009;59:520–4. - PMC - PubMed
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71. [Erratum, N Engl J Med 2007;357:100] - PubMed